Clinical trial
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
NCT00413075 · Valerio Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00413075 |
|---|---|
| Title | Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma |
| Official title | Open Label, Dose Escalation Trial of Oral PXD101 in Patients With Advanced Solid Tumors |
| Lead sponsor | Valerio Therapeutics, Industry |
| Collaborators | Spectrum Pharmaceuticals, Inc Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Solid Tumor, Lymphoma |
| Intervention type | Drug |
| Interventions | oral belinostat |
| Enrollment | 121 |
| Start date | Jun 1, 2006 |
| Primary completion | Aug 1, 2011 |
| Completion | Aug 1, 2011 |
| First posted | Dec 19, 2006 |
| Last update posted | Jul 8, 2015 |
| Countries | Denmark, United Kingdom, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: